REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
REGENXBIO (RGNX) has announced upcoming presentations of new interim biomarker data from their Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a treatment for Duchenne muscular dystrophy. The data will be presented at the 2025 MDA Clinical & Scientific Conference in Dallas from March 16-19, 2025.
Two presentations are scheduled: An interim clinical data presentation by Dr. Carolina Tesi Rocha from Stanford School of Medicine on March 19, and a pre-clinical research presentation on microdystrophin by Dr. Steven Foltz, Senior Scientist at REGENXBIO. Both presentations will be made available on REGENXBIO's website.
REGENXBIO (RGNX) ha annunciato prossime presentazioni di nuovi dati interinali sui biomarcatori del loro trial di Fase I/II AFFINITY DUCHENNE® relativo a RGX-202, un trattamento per la distrofia muscolare di Duchenne. I dati saranno presentati alla 2025 MDA Clinical & Scientific Conference a Dallas dal 16 al 19 marzo 2025.
Due presentazioni sono programmate: una presentazione di dati clinici interinali da parte della Dr.ssa Carolina Tesi Rocha della Stanford School of Medicine il 19 marzo, e una presentazione di ricerca pre-clinica sul microdistrofina da parte del Dr. Steven Foltz, Scienziato Senior presso REGENXBIO. Entrambe le presentazioni saranno rese disponibili sul sito web di REGENXBIO.
REGENXBIO (RGNX) ha anunciado próximas presentaciones de nuevos datos interinos de biomarcadores de su ensayo de Fase I/II AFFINITY DUCHENNE® sobre RGX-202, un tratamiento para la distrofia muscular de Duchenne. Los datos se presentarán en la 2025 MDA Clinical & Scientific Conference en Dallas del 16 al 19 de marzo de 2025.
Están programadas dos presentaciones: una presentación de datos clínicos interinos por la Dra. Carolina Tesi Rocha de la Stanford School of Medicine el 19 de marzo, y una presentación de investigación preclínica sobre microdistrofina por el Dr. Steven Foltz, Científico Senior en REGENXBIO. Ambas presentaciones estarán disponibles en el sitio web de REGENXBIO.
REGENXBIO (RGNX)는 Duchenne 근이영양증 치료제 RGX-202의 1/2상 AFFINITY DUCHENNE® 시험에서 새로운 중간 바이오마커 데이터 발표를 발표했습니다. 데이터는 2025년 3월 16일부터 19일까지 댈러스에서 열리는 2025 MDA Clinical & Scientific Conference에서 발표될 예정입니다.
두 개의 발표가 예정되어 있습니다: 3월 19일 스탠포드 의대의 Carolina Tesi Rocha 박사가 진행하는 중간 임상 데이터 발표와 REGENXBIO의 수석 과학자인 Steven Foltz 박사가 진행하는 마이크로디스트로핀에 대한 전임상 연구 발표입니다. 두 발표 모두 REGENXBIO 웹사이트에서 제공될 예정입니다.
REGENXBIO (RGNX) a annoncé des présentations à venir de nouvelles données intermédiaires sur les biomarqueurs de leur essai de Phase I/II AFFINITY DUCHENNE® concernant RGX-202, un traitement pour la dystrophie musculaire de Duchenne. Les données seront présentées lors de la 2025 MDA Clinical & Scientific Conference à Dallas du 16 au 19 mars 2025.
Deux présentations sont programmées : une présentation de données cliniques intermédiaires par Dr. Carolina Tesi Rocha de la Stanford School of Medicine le 19 mars, et une présentation de recherche préclinique sur la microdystrophine par Dr. Steven Foltz, Scientifique Senior chez REGENXBIO. Les deux présentations seront disponibles sur le site web de REGENXBIO.
REGENXBIO (RGNX) hat die bevorstehenden Präsentationen neuer Zwischen-Biomarker-Daten aus ihrer Phase I/II AFFINITY DUCHENNE®-Studie zu RGX-202, einer Behandlung für die Duchenne-Muskeldystrophie, angekündigt. Die Daten werden auf der 2025 MDA Clinical & Scientific Conference in Dallas vom 16. bis 19. März 2025 präsentiert.
Es sind zwei Präsentationen geplant: Eine Präsentation der Zwischen klinischen Daten durch Dr. Carolina Tesi Rocha von der Stanford School of Medicine am 19. März und eine Präsentation zur präklinischen Forschung über Mikrodystrophin durch Dr. Steven Foltz, Senior Scientist bei REGENXBIO. Beide Präsentationen werden auf der Website von REGENXBIO verfügbar sein.
- None.
- None.
Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)
Session: Clinical Trials
Date/Time: Wednesday, March 19, 2025; 8:15 a.m. CT
Presenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children's Health
Title: Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)
Session: Pre-Clinical Research
Presenter: Steven Foltz, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
The presentations will be available in the Publications section of REGENXBIO's website.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical--scientific-conference-302396530.html
SOURCE REGENXBIO Inc.
FAQ
What new data will RGNX present at the 2025 MDA Conference?
When and where will RGNX present their RGX-202 clinical trial results?
Who will present the RGNX clinical trial data at the 2025 MDA Conference?
What is the focus of RGNX's pre-clinical research presentation at MDA 2025?
